Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Immunate is indicated for disorders of the intrinsic coagulation pathway that involve deficiency of factor VIII or von Willebrand factor.

• Hemophilia A: provides missing factor VIII to improve clot formation and reduce bleeding episodes.
• von Willebrand disease: supplies von Willebrand factor to enhance platelet adhesion and stabilize factor VIII, improving hemostasis.
• Perioperative management: administered before surgery to prevent excessive bleeding in patients with these deficiencies.

• Immunate supplies exogenous human factor VIII and von Willebrand factor, which bind to platelet glycoprotein Ib receptors and stabilize circulating factor VIII. This restores the intrinsic pathway of the coagulation cascade, allowing formation of a stable fibrin clot and normalizing hemostasis in individuals lacking these proteins.

Adverse reactions reported with Immunate may vary in frequency and severity.

Common Side Effects

• Infusion‑related reactions such as chills, fever, or flushing.
• Headache or mild nausea.
• Arthralgia or joint discomfort.
• Transient increase in blood pressure.

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions.
• Development of inhibitory antibodies (inhibitors) against factor VIII or von Willebrand factor.
• Thrombotic events including deep‑vein thrombosis or pulmonary embolism.

When using Immunate, clinicians should observe several safety measures.

• Inhibitor monitoring: assess for development of anti‑factor VIII antibodies during therapy.
• Bleeding history: evaluate prior bleeding episodes and current anticoagulant use.
• Cardiovascular risk: use caution in patients with a history of thrombosis or cardiovascular disease.
• Hypersensitivity: discontinue if signs of severe allergic reaction occur.
• Concomitant pro‑coagulants: avoid simultaneous use with other clotting factor concentrates unless medically indicated.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate may interact with other medications that affect coagulation.

Major Interactions (Avoid)

• Concurrent use of other plasma‑derived clotting factor concentrates may increase risk of inhibitor formation.
• Administration with activated pro‑coagulant agents (e.g., recombinant factor VIIa) can heighten thrombosis risk.
• High‑dose estrogen therapy may exacerbate thrombotic potential when combined.

Moderate Interactions (Monitor Closely)

• Anticoagulants such as warfarin or direct oral anticoagulants may alter hemostatic balance; monitor coagulation parameters.
• NSAIDs and aspirin can increase bleeding tendency; assess bleeding risk.
• Immunosuppressive drugs may affect inhibitor development; observe antibody titres.